Then perhaps I have posted the information about the exon-skipping therapeutic in an inappropriate forum. RNA-level drugs have no established niche of their own. If we consider "gene therapy" to be the same as "nucleic acid sequence-based therapy" then the exon-skipping oligos are gene therapy. However, I lean toward agreeing with you that gene therapy should be a term reserved for DNA-level changes. Perhaps the term "transcript therapy" would capture the class of RNA-modifying drugs clearly.